Cytiva, the former GE Healthcare Life Sciences, as well as Pall Corp., which specializes in high-tech filtration, separation and purification, announced on Tuesday a plan to invest $1.5 billion dollars over two years to meet what the companies called growing demand for biotechnology solutions.
Both Cytiva and Pall Corp., which have outposts in Shrewsbury, Westborough and Marlborough, are part of the larger Danaher Life Sciences platform, based in Washington, DC.
The investment, which is already underway, will include $600 million set aside for chromatography resins, $400 million toward cell culture media, $300 million toward single-use technologies, $200 million toward expansion across the companies’ sites and the hiring of 2,000 plus full-time employees, according to a press release.Â
The new investment follows a 2020 announcement from Cytiva, when the company said it would spend $500 million on building capacity. That investment funded a new manufacturing facility in Shrewsbury and a new cleanroom in Westborough.
The announcement comes after both companies completed a spate of acquisitions, including Cytiva’s acquisitions of Vanrx Pharmasystems of Canada, GoSilico of Germany and Intermountain Life Sciences of Utah. Pall, in turn, acquired Austar of China and Precision NanoSystems of Canada.Â
All acquisitions took place this year.
